vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2014 - 2026)

vTv Therapeutics has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $87.6 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 231.19% year-over-year to $87.6 million; the TTM figure through Jun 2026 stood at $375.8 million (up 168.61% YoY), while the FY2025 annual figure was $89.9 million, up 134.93% from the prior year.
• Liabilities and Shareholders Equity came in at $87.6 million for Q2 2026 at vTv Therapeutics, down from $98.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $99.5 million in Q3 2025 to a low of $11.0 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 5 years is $45.5 million, with a median of $36.3 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity slumped 66.85% in 2023 and soared 247.3% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $33.2 million in 2022, then tumbled by 66.85% to $11.0 million in 2023, then soared by 247.3% to $38.3 million in 2024, then jumped by 134.93% to $89.9 million in 2025, then fell by 2.57% to $87.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $87.6 million in Q2 2026, $98.8 million in Q1 2026, and $89.9 million in Q4 2025.